Rna Diagnostics Inc.

Rna Diagnostics Inc. is a clinical stage molecular diagnostics company for personalized cancer therapy management. We are working with physicians around the globe to improve cancer treatment and the quality of life for patients, while reducing healthcare costs. Our predictive biomarker platform technology, Veridapt DX™, now in clinical trials, is designed to measure early solid tumor response to neoadjuvant cancer treatment. The Veridapt DX predictive biomarker identifies non-responsive solid tumors by monitoring the degree of RNA (rRNA) disruption in the cells. Once validated, the test will enable physicians to escalate or de-escalate therapy, or select an alternative strategy, as early as 5 weeks into a standard 6-month treatment regimen. A series of pre-clinical studies, and retrospective and ongoing prospective clinical data, have shown strong evidence for clinical effectiveness. A large-scale study is now under way to validate Veridapt DX (formerly known as the RNA Disruption Assay) as a tool to manage primary breast cancer treatment: the Breast Cancer Response Evaluation for Individualized Therapy (BREVITY) clinical trial. Phase 1 results, published in JNCI Cancer Spectrum, demonstrate Veridapt DX's strong capability (Negative Predictive Value >93%) to accurately predict therapy efficacy/outcomes during early treatment. Phase 2 is now under way in 7 countries. Our initial focus is on primary breast cancer; however, our assay platform has the potential to apply to any solid tumor and any cancer drug therapy for personalized, precision medicine. We welcome inquiries from clinicians interested in collaborative trials for early assessment of treatment for solid tumor cancers.

• Employees 12
• Founded 2010
• Annual Revenue $5000000
• Total Funding $11314090